Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Carboxypeptidase A1 (CPA1) is a zinc-dependent metalloprotease enzyme primarily produced in the pancreas. It plays a key role in protein digestion by cleaving C-terminal branched-chain and aromatic amino acids from dietary proteins. It is also involved in zymogen inhibition, being synthesized as an inactive precursor to prevent autodigestion of pancreatic tissue. Mutations in CPA1 have been linked to chronic pancreatitis, and elevated serum levels are observed in pancreatic cancer. Immunohistochemical staining for CPA1 serves as a diagnostic marker for pancreatic acinar cell carcinoma.
Hydrolyzes peptide bonds at the C-terminal end of proteins, specifically targeting branched-chain and aromatic amino acids.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Carboxypeptidase A1 (CPA1).